Cite
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATED IN ITALY ACCORDING TO THE IBRUTINIB NAMED PATIENT PROGRAM: THE REAL LIFE RESULTS
MLA
Morigi, A., et al. Effectiveness and Safety of Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program: The Real Life Results. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..02e1766d4d8099249285a9c84ffa913f&authtype=sso&custid=ns315887. Accessed 9 Oct. 2024.
APA
Morigi, A., Federico Sottotetti, Gotti, M., Spina, M., Volpetti, S., Ferrero, S., Spina, F., Pisani, F., Merli, M., Visco, C., Paolini, R., Zilioli, V. R., Baldini, L., Di Renzo, N., Tosi, P., Cascavilla, N., Molica, S., Ilariucci, F., Rigolin, G. M., … Zinzani, P. L. (n.d.). Effectiveness and Safety of Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program: The Real Life Results.
Chicago
Morigi, A., Federico Sottotetti, M. Gotti, M. Spina, S. Volpetti, S. Ferrero, F. Spina, et al. 2024. “Effectiveness and Safety of Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program: The Real Life Results.” Accessed October 9. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..02e1766d4d8099249285a9c84ffa913f&authtype=sso&custid=ns315887.